Toll Free: 1-888-928-9744

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 41 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape.

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Gorlin Syndrome (Basal Cell Nevus Syndrome) - Overview Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Gorlin Syndrome (Basal Cell Nevus Syndrome) - Companies Involved in Therapeutics Development Adgero Biopharmaceuticals Holdings Inc Galderma SA Mayne Pharma Group Ltd Transgene SA Gorlin Syndrome (Basal Cell Nevus Syndrome) - Drug Profiles itraconazole - Drug Profile Product Description Mechanism Of Action R&D Progress patidegib hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress rostaporfin - Drug Profile Product Description Mechanism Of Action R&D Progress TG-1042 - Drug Profile Product Description Mechanism Of Action R&D Progress trifarotene - Drug Profile Product Description Mechanism Of Action R&D Progress Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products Gorlin Syndrome (Basal Cell Nevus Syndrome) - Product Development Milestones Featured News & Press Releases May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Galderma SA, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Mayne Pharma Group Ltd, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Transgene SA, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects, H2 2017 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products, H2 2017


List of Figures
Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Targets, H2 2017 Number of Products by Stage and Targets, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify